Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × TNBC × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 595 Breast Neoplasms 527 Neoplasms 492 Leukemia, Myeloid, Acute 407 Colorectal Neoplasms 374 Multiple Myeloma 362 Melanoma 353 Prostatic Neoplasms 310 Neoplasm Metastasis 305 Pancreatic Neoplasms 304 Lymphoma 283 Recurrence 277 Ovarian Neoplasms 273 Lung Neoplasms 248 Leukemia 245 Lymphoma, Non-Hodgkin 242 Glioblastoma 231 Stomach Neoplasms 209 Precursor Cell Lymphoblastic Leukemia-Lymphoma 209 Leukemia, Lymphocytic, Chronic, B-Cell 194 Carcinoma, Hepatocellular 192 Squamous Cell Carcinoma of Head and Neck 179 Myelodysplastic Syndromes 179 Lymphoma, Large B-Cell, Diffuse 176 Carcinoma, Renal Cell 170 Brain Neoplasms 149 Lymphoma, Follicular 147 Head and Neck Neoplasms 141 Triple Negative Breast Neoplasms 136 Lymphoma, Mantle-Cell 135

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918133 2025-03-11

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Biotheus Inc.

Phase 1/2 Active not recruiting

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡